Skip to main content
. 2017 Dec 18;29(3):694–699. doi: 10.1093/annonc/mdx795

Figure 1.

Figure 1.

Diagram of phase I–II trial design. Based on the most recent data, the optimal dose is defined as the dose that maximizes the efficacy–toxicity trade-off.